ReNeuron
| Public company | |
| Traded as | LSE: RENE |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
| Website | reneuron.com |
ReNeuron is a UK-based stem cell research company whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
ReNeuron is currently testing the effects of neural stem cells on spinal cords for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
See also
References
- ↑ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ↑ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links
This article is issued from Wikipedia - version of the 9/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.